March 2017 FDA Recall Rivastigmine Tartrate by Dr. Reddy's Laboratories, Inc.
D-0649-2017 - Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.

This Class III drug recall was voluntarily initiated by Dr. Reddy's Laboratories, Inc. on March 6, 2017 for the product Rivastigmine Tartrate. The FDA reported the reason for recall as cross-contamination with other products -related substances test for rivastigmine tartrate capsules usp, 1.5 mg showed a peak for ranitidine.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0649-2017

Reason for Recall
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Initiated
03-06-2017
Reported
04-12-2017
Quantity
1,728 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Dr. Reddy's Laboratories, Inc.
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60

Batch or Lot Expiration Information

Lot# C607323, Exp 10/18